Juliet Thompson has over 30 years of finance, banking and board experience with significant focus on the healthcare sector. Juliet is a proven FTSE 250 non-executive and audit chair and a former investment banker who has spent her career advising life science companies. She played a leading role in setting up Code Securities, which was quickly acquired by Nomura (becoming Nomura Code) but remained independent.
At Nomura Code, Juliet was advising companies on their financing and strategic options. She worked on over 50 transactions including IPO’s, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences team. Since leaving the City, Juliet has built a diverse portfolio; she currently chairs the Audit Committee of Indivior PLC (FTSE 250) and Novacyt, both listed companies and is also a Non-Executive Director of Organox, a private company spun out of Oxford University. She previously served on the Board of Vectura plc,(FTSE 250) as well as GI Dynamics, a Boston-based medical device company. She holds a BSc in Economics from the University of Bristol and is a Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants.
